Depression Research Unit, Universityof Pennsylvania School of Medicine
Philadelphia, Pennsylvania, 19104-3309, United States
NCT Number: NCT00645983
This study will determine the effectiveness of chamomile extract for treating generalized anxiety disorder.
Study hypotheses: 1)Chamomile extract will have a superior anti-anxiety effect compared to placebo. 2)Chamomile will have a comparable safety profile to that of placebo.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Philadelphia, Pennsylvania, 19104-3309, United States
We propose to investigate the anti-anxiety activity of Chamomile. Among the many uses of Chamomile, its use as an anti-anxiety herb is universal. Despite its widespread use and acceptance, there have been no studies evaluating the safety and anti-anxiety efficacy of Chamomile in human subjects. Given this lack of controlled clinical data, we propose a pilot study of Chamomile safety and efficacy in mild anxiety, and propose using the data as a basis for statistically powering a future R01 application. We will ask: Is Chamomile a safe and effective alternative treatment for Generalized Anxiety Disorder (GAD)? To do this, 60 patients with a diagnosis of mild to moderate GAD will receive double-blind treatment for 8 weeks with either (i) Chamomile extract, or (ii) placebo. We hypothesize that Chamomile will have a superior anti-anxiety efficacy compared to placebo, and a comparable safety profile to placebo.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Men and women > 18 years of age (all races and ethnicity)
Meet DSM IV criteria for GAD
Mild to moderate symptom severity
HAM-A score > 8
Not receiving anti-anxiety medication (e.g., benzodiazepine, venlafaxine, buspirone, or SSRI)
Able to understand and provide signed informed consent
Able to participate in a 8-week study
Exclusion criteria
Patients < 18 years old
Current DSM IV Axis I diagnosis of Major Depressive Disorder, Bipolar Disorder, Panic Disorder (with or without agoraphobia), Specific Phobia Disorder, Obsessive-Compulsive Disorder, Posttraumatic Stress Disorder, Acute Stress Disorder, Substance-Induced Anxiety Disorder, Schizophrenia, Other psychotic disorders, Current alcohol or drug abuse, Alcohol or drug dependence within 3 months, [NB: Patients with co-morbid DSM IV Axis I Depressive Disorders NOS (e.g., minor depressive disorder, premenstrual dysphoric disorder, and recurrent brief depressive disorder will not be excluded)]
Unstable medical condition (e.g., hypothyroidism, hypertension, myocardial infarction within 1 month, neoplastic condition)
Allergy to Chamomile preparation
Allergy to plants of the asteraceae family (e.g., ragweed, asters, chrysanthemum)
Allergy to mugwort, RAST, or birch tree pollen
Concurrent tranquilizer, antidepressant or mood stabilizer therapy
Concurrent use of over-the-counter anti-anxiety and/or antidepressant preparations (e.g., Chamomile, St. John's Wort, Kava kava)
Women of child-bearing potential not willing to employ a medically proven form of contraception (e.g., condoms, oral contraceptives, etc)
220 mg - 1100 mg daily
1 to 5 capsules daily
Time frame: 8 Weeks
Time frame: 8 Weeks
University of Pennsylvania
Other
Chamomile Therapy for Generalized Anxiety Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05503017
Anxiety Disorders, Generalized Anxiety Disorder
Tallahassee, Florida, United States
View Trial DetailsNCT03585010
Anxiety Disorder of Childhood, Anxiety Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT07452835
Anxiety Disorders, Depressive Disorder
Cairo, Menofia, Egypt
View Trial DetailsNCT06046170
Anxiety, Anxiety Disorders
Baltimore, Maryland, United States
View Trial Details